Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2010

View Archived Issues

Novel M. tuberculosis methionine aminopeptidase inhibitors identified

Variations in fentanyl sensitivity correlated with OPRM1 gene polymorphisms

Gene recurrence score may be useful for prognosis in node-positive breast cancer

Javelin reports phase III trial data for Ereska

Nymox provides update on pivotal phase III NX-1207 trials for BPH

Phase II study evaluates droxidopa in combination with carbidopa in adult ADHD

StemCells' HuCNS-SC human neural stem cells used in myelination disorder trial

FDA accepts Alexza's AZ-004 NDA for filing

Data Monitoring Committee recommends continuation of phase III StemEx trial

Correlation between higher blood lead levels and adverse mental health outcomes

Oral cladribine reduces rate of multiple sclerosis relapse in phase III trial

LEK Pharmaceuticals describes novel broad spectrum antibacterial agents

Amura Therapeutics discovers novel CAC1 cysteine protease inhibitors

Aegera presents novel IAP inhibitors

Otsuka Pharmaceutical describes novel monoamine reuptake inhibitors

Ligon Discovery and Lycera collaborate to develop drugs for immune disorders

Data Monitoring Committee recommends continuation of phase III ThermoDox trial

QRxPharma initiates second pivotal phase III MoxDuoIR dual-opioid trial

Antisense provides update on ATL-1101

Astellas reports third quarter 2009 results

Lundbeck claims the identification of novel PDE10 inhibitors

FDA grants approval to Daiichi's hypertension treatment Benicar in pediatric patients

Living Cell Technologies receives government grant for Diabecell

3SBio and Ascentage enter into strategic alliance for targeted cancer therapeutics

Shenogen and Chemizon sign agreement for ERalpha receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...